Oxford Biomedica Regulatory News (OXB)

10 Mar 2008 08:52

Oxford Biomedica PLC10 March 2008 FOR IMMEDIATE RELEASE 10 MARCH 2008 OXFORD BIOMEDICA APPOINTS DR ALEX LEWIS AS NON-EXECUTIVE DIRECTOR Oxford, UK - 10 March 2008: Oxford BioMedica (LSE: OXB), a leading gene therapycompany, announced today that Dr Alexander D Lewis will join the Board on 3April 2008 as a Non-executive Director and member of the Remuneration and AuditCommittees. Dr Lewis is an experienced consultant to the pharmaceutical and biotech industrywith a background of over 20 years in medical research and drug development.Until 1 January 2008, Dr Lewis was head of the Partnering and Due DiligencePractice at leading consultants Wood Mackenzie and was based in their Bostonoffice. Dr Lewis' assignments have involved supporting investment banks withtheir corporate finance activities, including selection of acquisition targets,due diligence, expert reports and listing particulars; as well as advisingpharmaceutical and biotech clients with their licensing strategy for in and outlicensing and asset identification, general corporate strategy in terms ofresearch and development and also mergers and acquisitions; and also performingdue diligence on companies, products and technologies. Dr Lewis has also beeninvolved in the provision of the expert reports and technical advice for InitialPublic Offerings (IPO's) and fundraising activities of biotech companies basedin the USA and Europe. Professor Alan Kingsman, Chief Executive Officer of Oxford BioMedica, said: "Weare delighted that Alex has agreed to join the board of Oxford BioMedica. Hisexceptional experience and broad-based knowledge will complement the existingteam and help take the Company forward through its next exciting stages ofcommercial and operational development." There is no other information to be disclosed under Paragraph 9.6.13 R of theListing Rules. -Ends- For further information, please contact:Oxford BioMedica plc: Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000JPMorgan Cazenove Limited: James Mitford/ Gina Gibson Tel: +44 (0)20 7588 2828City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Tel: +44 (0)20 7466 5000Buchanan CommunicationsScientific/Trade Press Enquiries: Gemma Price/ Holly Griffiths/ Katja Stout Tel: +44 (0)20 7457 2020 College Hill Life SciencesUS Enquiries: Thomas Fechtner Tel: (646) 378 2900 The Trout Group LLC Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising incancer immunotherapy and gene-based therapies. The Company was established in1995, as a spin-out from Oxford University, and is listed on the London StockExchange. The Company has a platform of gene delivery technologies, which are based onhighly engineered viral systems. Oxford BioMedica also has in-house clinical,regulatory and manufacturing know-how. The lead product candidate is TroVax(R),an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventisfor global development and commercialisation. TroVax is in Phase IIIdevelopment. Oxford BioMedica has three other products in clinical development,including ProSavin(R), a novel gene-based treatment for Parkinson's disease, ina Phase I/II trial. The Company is underpinned by over 80 patent families, whichrepresent one of the broadest patent estates in the field. The Company has astaff of approximately 85. Oxford BioMedica has collaborations withsanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licenseesinclude Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock Exchange